Cytek BioSciences Profit Margin

The latest profit margin for CTKB is -36.25% as of March 2026. That compares with -5.71% in the prior-year period — down 534.7% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Cytek BioSciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTKB's profit margin moved from -5.71% to -36.25% — a 534.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cytek BioSciences's valuation or profitability profile.

Against Healthcare companies, CTKB currently prints -36.25% for profit margin, while the sector average sits near 15.29%. That is roughly 337.0% below the sector mean. Large gaps often invite a closer look at Cytek BioSciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Cytek BioSciences converts resources into returns. At -36.25%, CTKB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5.71% in the prior-year period — down 534.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CTKB's profit margin (-36.25%), review year-over-year change from -5.71%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.